334 related articles for article (PubMed ID: 21204588)
1. The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis.
Halpern R; Becker L; Iqbal SU; Kazis LE; Macarios D; Badamgarav E
J Manag Care Pharm; 2011; 17(1):25-39. PubMed ID: 21204588
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
Martin KE; Yu J; Campbell HE; Abarca J; White TJ
J Manag Care Pharm; 2011 Oct; 17(8):596-609. PubMed ID: 21942301
[TBL] [Abstract][Full Text] [Related]
3. Examining the Effect of Medication Adherence on Risk of Subsequent Fracture Among Women with a Fragility Fracture in the U.S. Medicare Population.
Keshishian A; Boytsov N; Burge R; Krohn K; Lombard L; Zhang X; Xie L; Baser O
J Manag Care Spec Pharm; 2017 Nov; 23(11):1178-1190. PubMed ID: 29083977
[TBL] [Abstract][Full Text] [Related]
4. Association between osteoporosis treatment change and adherence, incident fracture, and total healthcare costs in a Medicare Advantage Prescription Drug plan.
Ward MA; Xu Y; Viswanathan HN; Stolshek BS; Clay B; Adams JL; Kallich JD; Fine S; Saag KG
Osteoporos Int; 2013 Apr; 24(4):1195-206. PubMed ID: 23100119
[TBL] [Abstract][Full Text] [Related]
5. Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study.
Hazel-Fernandez L; Louder AM; Foster SA; Uribe CL; Burge RT
BMC Musculoskelet Disord; 2013 Jan; 14():4. PubMed ID: 23281846
[TBL] [Abstract][Full Text] [Related]
6. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
[TBL] [Abstract][Full Text] [Related]
7. Direct healthcare costs of osteoporosis-related fractures in managed care patients receiving pharmacological osteoporosis therapy.
Viswanathan HN; Curtis JR; Yu J; White J; Stolshek BS; Merinar C; Balasubramanian A; Kallich JD; Adams JL; Wade SW
Appl Health Econ Health Policy; 2012 May; 10(3):163-73. PubMed ID: 22510025
[TBL] [Abstract][Full Text] [Related]
8. Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis.
Cotté FE; Mercier F; De Pouvourville G
Clin Ther; 2008 Dec; 30(12):2410-22. PubMed ID: 19167600
[TBL] [Abstract][Full Text] [Related]
9. Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis.
Liu J; Guo H; Rai P; Pinto L; Barron R
Osteoporos Int; 2018 Nov; 29(11):2409-2417. PubMed ID: 30022254
[TBL] [Abstract][Full Text] [Related]
10. Cost and consequences of noncompliance with osteoporosis treatment among women initiating therapy.
Modi A; Siris ES; Tang J; Sen S
Curr Med Res Opin; 2015 Apr; 31(4):757-65. PubMed ID: 25661017
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and Treatment of Osteoporosis Before and After Fracture: A Side-by-Side Analysis of Commercially Insured and Medicare Advantage Osteoporosis Patients.
Weaver J; Sajjan S; Lewiecki EM; Harris ST
J Manag Care Spec Pharm; 2017 Jul; 23(7):735-744. PubMed ID: 28650253
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and Cost of Subsequent Fractures Among U.S. Patients with an Incident Fracture.
Weaver J; Sajjan S; Lewiecki EM; Harris ST; Marvos P
J Manag Care Spec Pharm; 2017 Apr; 23(4):461-471. PubMed ID: 28345441
[TBL] [Abstract][Full Text] [Related]
13. Characterizing pulmonary hypertension-related hospitalization costs among Medicare Advantage or commercially insured patients with pulmonary arterial hypertension: a retrospective database study.
Burke JP; Hunsche E; Régulier E; Nagao M; Buzinec P; Drake Iii W
Am J Manag Care; 2015 Jan; 21(3 Suppl):s47-58. PubMed ID: 25734573
[TBL] [Abstract][Full Text] [Related]
14. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
15. Direct and indirect costs of non-vertebral fracture patients with osteoporosis in the US.
Pike C; Birnbaum HG; Schiller M; Sharma H; Burge R; Edgell ET
Pharmacoeconomics; 2010; 28(5):395-409. PubMed ID: 20402541
[TBL] [Abstract][Full Text] [Related]
16. Cost and management of males with closed fractures.
Brenneman SK; Yurgin N; Fan Y
Osteoporos Int; 2013 Mar; 24(3):825-33. PubMed ID: 22776864
[TBL] [Abstract][Full Text] [Related]
17. Cost of fractures commonly associated with osteoporosis in a managed-care population.
Christensen L; Iqbal S; Macarios D; Badamgarav E; Harley C
J Med Econ; 2010; 13(2):302-13. PubMed ID: 20482324
[TBL] [Abstract][Full Text] [Related]
18. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.
Tosteson AN; Burge RT; Marshall DA; Lindsay R
Am J Manag Care; 2008 Sep; 14(9):605-15. PubMed ID: 18778176
[TBL] [Abstract][Full Text] [Related]
19. Medical costs of osteoporosis in the elderly Medicare population.
Blume SW; Curtis JR
Osteoporos Int; 2011 Jun; 22(6):1835-44. PubMed ID: 21165602
[TBL] [Abstract][Full Text] [Related]
20. The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature.
Fleurence RL; Iglesias CP; Johnson JM
Pharmacoeconomics; 2007; 25(11):913-33. PubMed ID: 17960951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
